We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Xeljanz Meets Primary Endpoints in Two Ulcerative Colitis Trials
Pfizer’s Xeljanz Meets Primary Endpoints in Two Ulcerative Colitis Trials
Pfizer’s oral Xeljanz sent more patients suffering from moderate to severe ulcerative colitis into remission, meeting primary endpoints in two Phase 3 clinical trials, the company reported Monday.